🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Primary Biliary Cirrhosis

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a1 site📍 Sioux Falls Sanford Health An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis NCT05335603n/a1 site📍 Hvidovre University of Copenhagen A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA NCT07282353Phase 342 sites📍 Hefei📍 Hefei📍 Hefei Cascade Pharmaceuticals, Inc · Tests: 2mg CS0159, Placebo Austrian PBC Registry NCT07598669n/a11 sites📍 Klagenfurt📍 Sankt Pölten📍 Salzburg Medical University of Vienna FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy NCT07296458Phase 31 site📍 Xi'an Xijing Hospital of Digestive Diseases · Tests: Fenofibrate, UDCA (Ursodeoxycholic acid) Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP) NCT07205874n/a1 site📍 Madrid Hospital Universitario La Paz RELIEF: Multimodal Prehabilitation to Treat Fatigue in Patients With Primary Biliary Cholangitis NCT07161245NA1 site📍 Barcelona Hospital Clinic of Barcelona · Tests: Multimodal prehabilitation, standard of care Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease NCT06825559Phase 11 site📍 Indianapolis Zydus Therapeutics Inc. · Tests: Saroglitazar Magnesium 1 mg Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid NCT02823366Phase 31 site📍 Xi'an Xijing Hospital of Digestive Diseases · Tests: Fenofibrate, UDCA Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes NCT07216235Phase 33 sites📍 Marietta📍 Indianapolis📍 Houston Zydus Therapeutics Inc. · Tests: Saroglitazar magnesium 1 mg, Placebo Detection Program for Patients With Primary Biliary Cholangitis Lost in the System NCT05919433n/a1 site📍 Terrassa Hospital Mutua de Terrassa Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome NCT06519162n/a1 site📍 Daejeon Chungnam National University Hospital Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study NCT06755541Phase 31 site📍 Xi'an Xijing Hospital of Digestive Diseases · Tests: Fenofibrate in Combination With Ursodeoxycholic Acid Biobank for Cholestatic Liver Diseases. NCT03445585n/a1 site📍 Rochester Mayo Clinic Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis NCT06051617Phase 3217 sites📍 Birmingham📍 Phoenix📍 Lancaster Gilead Sciences · Tests: Seladelpar, Placebo Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy NCT07556913n/a1 site📍 Wilmington Ipsen · Tests: Elafibranor Spanish Registry of Autoimmune and Cholestatic Liver Diseases (ColHai) NCT06767605n/a1 site📍 Barcelona Asociación Española para el Estudio del Hígado Fenofibrate in Primary Biliary Cholangitis: a Real World Study NCT06755151Phase 31 site📍 Xi'an Xijing Hospital of Digestive Diseases · Tests: Fenofibrate A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis NCT06016842Phase 3198 sites📍 Tucson📍 Little Rock📍 Coronado Ipsen · Tests: Elafibranor, Matched 80 mg placebo Efficacy and Safety of Bezafibrate 400 mg and Bezafibrate 200 mg as Adjunctive Treatments in Patients With Primary Biliary Cholangitis and Non-optimal Biochemical Response to Ursodeoxycholic Acid Therapy NCT06443606Phase 31 site📍 Paris Assistance Publique - Hôpitaux de Paris · Tests: Bezafibrate 400 mg in addition to UDCA therapy, Bezafibrate 200 mg in addition to UDCA therapy, Placebo in addition to … Canadian Network for Autoimmune Liver Disease NCT03569826n/a15 sites📍 Calgary📍 Edmonton📍 Vancouver University Health Network, Toronto · Tests: Observational; no intervention A Study of SIPLIZUMAB in AILD and LT Patients NCT06455280Phase 11 site📍 New York Elizabeth C. Verna · Tests: Siplizumab A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions NCT06864195n/a1 site📍 London Imperial College London Clinical Research of Tapering UDCA in PBC Patients With a Complete Response NCT04650243Phase 41 site📍 Beijing Peking Union Medical College Hospital · Tests: ursodeoxycholic acid LEOPARD Prospective Validation Cohort 1 NCT06723275n/a8 sites📍 Ghent📍 Clichy📍 Créteil Assistance Publique - Hôpitaux de Paris · Tests: Standardized assessments, guided tumor biopsy and biobanking, Standardized assessments and biobanking PBC Long-term Outcomes Study NCT07149675n/a1 site📍 Beijing Beijing Friendship Hospital Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis NCT05751967Phase 37 sites📍 Lanzhou📍 Guangzhou📍 Nanjing Xijing Hospital of Digestive Diseases · Tests: Placebo Combined With Ursodeoxycholic Acid, Fenofibrate Combined With Ursodeoxycholic Acid Swiss Primary Biliary Cholangitis Cohort Study NCT03146910n/a13 sites📍 Lugano📍 Basel📍 Bern Fondazione Epatocentro Ticino sCD163 in PBC Patients - Assessment of Treatment Response NCT02931513n/a1 site📍 Aarhus C University of Aarhus · Tests: Blood samples, Fibroscan, Questionnaires, Liver biopsy National Database on Primary Biliary Cholangitis NCT05151809n/a55 sites📍 Ancona📍 Bari📍 Bergamo University of Milano Bicocca · Tests: Clinical information
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy